

Contents

List of Contributors

I

THEORIES AND TECHNIQUES IN THE CHARACTERIZATION OF DRUG SUBSTANCES AND EXCIPIENTS

1. Solubility of Pharmaceutical Solids

R.V. MANTRI, R. SANGHVI, AND H.(J.) ZHU

1.1 Introduction	3
1.2 Thermodynamics of Solutions	5
1.3 Theoretical Estimation of Solubility	6
1.4 Solubilization of Drug Candidates	10
1.5 Experimental Determination of Solubility	18
References	21

2. Crystalline and Amorphous Solids

G.G.Z. ZHANG AND D. ZHOU

2.1 Introduction	23
2.2 Definitions and Categorization of Solids	23
2.3 Thermodynamics and Phase Diagrams	25
2.4 Pharmaceutical Relevance and Implications	34
2.5 Transformations Among Solids	38
2.6 Methods of Generating Solids	42
2.7 Amorphous Drugs and Solid Dispersions	43
2.8 Special Topics	52
References	53

3. Solid-State Characterization and Techniques

D. LAW AND D. ZHOU

3.1 Introduction	59
3.2 Microscopy	60
3.3 Powder X-ray Diffraction	64
3.4 Thermal Analysis	67
3.5 Vibrational Spectroscopy	72
3.6 Moisture Sorption	79
3.7 Hyphenated Techniques	81
3.8 Conclusion	82
References	82

xiii

4. API Solid-Form Screening and Selection

M.Y. GOKHALE AND R.V. MANTRI

4.1 Introduction	85
4.2 Solid-Form Selection Considerations	86
4.3 Screening Solid-Forms of API	102
4.4 Identification and Analysis of Forms	105
4.5 Conclusions	107
4.6 Case Studies	107
References	109

5. Drug Stability and Degradation Studies

D. ZHOU, W.R. PORTER AND G.G.Z. ZHANG

5.1 Introduction	113
5.2 Chemical Stability	113
5.3 Common Pathways of Drug Degradation	128
5.4 Experimental Approaches to Studying the Chemical Degradation of Drugs	134
5.5 Physical Stability and Phase Transformations	140
5.6 Phase Transformations During Pharmaceutical Processing	142
References	146

6. Excipient Compatibility and Functionality

A.S. NARANG, R.V. MANTRI AND K.S. RAGHAVAN

6.1 Introduction	151
6.2 Excipient Functionality	152
6.3 Excipient Compatibility	155
6.4 Excipient Variability	169
6.5 Risk Assessment of Drug-Excipient Incompatibilities and Mitigation Strategies	174
6.6 Conclusions	175
References	175

7. Polymer Properties and Characterization

J. BRADY, T. DÜRIG, PI. LEE AND J.-X. LI

7.1 Introduction	181
7.2 Basic Concepts and Characterization of Polymeric Materials	185
7.3 Commonly Used Polymer Excipients in Solid Oral Products	206
7.4 Conclusion	220
References	221

8. Interfacial Phenomena		12. Oral Drug Absorption: Evaluation and Prediction	
E. HADJITTOFIS, S.C. DAS, G.G.Z. ZHANG AND J.Y.Y. HENG		Y. YANG, Y. ZHAO, A. YU, D. SUN AND L.X. YU	
8.1 Interfaces	225	12.1 Introduction	331
8.2 Fundamental Intermolecular Forces	226	12.2 Anatomy and Physiology of the GI Tract	331
8.3 Thermodynamics of Particles in Electrolyte Solutions	228	12.3 Biopharmaceutics Classification System	332
8.4 Surface Tension and Surface Energy	229	12.4 Intestinal Permeability Evaluation: Cultured Cells	338
8.5 Thermodynamics of Wetting	232	12.5 Intestinal Permeability Evaluation: Ex Vivo	342
8.6 Solid–Vapor Interface	236	12.6 In Silico Methods	346
8.7 Interfacial Phenomenon (Solid–Solid)	241	12.7 In Vivo Methods to Determine Oral Drug Absorption	347
8.8 Future Directions—Opinions	246	12.8 Food Effects on Drug Intestinal Absorption	348
References	247	12.9 Regional Drug Absorption Along GI	350
9. Fundamental of Diffusion and Dissolution		12.10 Future Trends	352
Y. CHEN, J. WANG AND D.R. FLANAGAN		12.11 Conclusions	352
9.1 Fundamental of Diffusion	253	Disclaimer	352
9.2 Fundamentals of Dissolution	262	References	352
References	270	13. Dissolution Testing of Solid Products	
10. Particle, Powder, and Compact Characterization		Y. CHEN, Z. GAO AND J.Z. DUAN	
G.E. AMIDON, P.J. MEYER AND D.M. MUDIE		13.1 Introduction	355
10.1 Introduction	271	13.2 Theory of Dissolution Test for Solid Drug Products	356
10.2 Particle Size Characterization	271	13.3 Current Technology and Instrumentation for Dissolution Testing	358
10.3 Powder Characterization	276	13.4 Regulatory Considerations	364
10.4 Compact (Mechanical Property) Characterization	281	13.5 Summary	378
10.5 Conclusions	290	References	379
References	290	14. Bioavailability and Bioequivalence	
II		H. ZHU, B.V. LI, R.S. UPPOOR, M. MEHTA AND L.X. YU	
BIOPHARMACEUTICAL AND PHARMACOKINETIC EVALUATIONS OF DRUG MOLECULES AND DOSAGE FORMS		14.1 General Background	381
11. Oral Absorption Basics: Pathways and Physicochemical and Biological Factors Affecting Absorption		14.2 Definitions and Key Concepts	382
L. ZHU, L. LU, S. WANG, J. WU, J. SHI, T. YAN, C. XIE, Q. LI, M. HU AND Z. LIU		14.3 General Components of BA and BE Studies	384
11.1 Barriers to Oral Drug Delivery	297	14.4 Data Analysis for BA and BE Studies	387
11.2 Pathways of Drug Absorption	298	14.5 Special Topics for BA and BE Assessment	389
11.3 Pathways of Drug Metabolism	307	14.6 Biowaiver and BCS	393
11.4 Pathways of Drug Elimination	312	14.7 Summary and Future Perspectives	395
11.5 Coupling of Enzymes and Efflux Transporters	315	References	395
11.6 Regulation of Transporters and Enzymes by Nuclear Receptors	319	15. Predictive Biopharmaceutics and Pharmacokinetics: Modeling and Simulation	
11.7 Physicochemical Factors Affecting Drug Absorption	321	Y. YANG, Y. ZHAO, J.Z. DUAN, P. ZHAO, L. ZHAO AND X. ZHANG	
11.8 Biological Factors Affecting Drug Absorption	323	15.1 Introduction	399
References	325	15.2 Modeling and Simulation Approaches for Biopharmaceutics and PK	400
		15.3 Application of Biopharmaceutics and PK Modeling and Simulation in Drug Development	407
		15.4 Application of Biopharmaceutics and PK Modeling and Simulation in Regulatory Activities	408
		15.5 Summary	409
		References	409

16. In Vitro/In Vivo Correlations: Fundamentals, Development Considerations, and Applications

Y. QIU AND J.Z. DUAN

16.1 Introduction	415
16.2 Development and Assessment of an IVIVC	416
16.3 Considerations in IVIVC Development	430
16.4 IVIVC Development Approach	435
16.5 Applications and Limitations	439
16.6 Case Studies	441
16.7 Summary	447
References	447

III

DESIGN, DEVELOPMENT AND SCALE-UP OF FORMULATION AND MANUFACTURING PROCESS

17. Oral Formulations for Preclinical Studies: Principle, Design, and Development Considerations

Y. GAO, C. GESENBURG AND W. ZHENG

17.1 Introduction	455
17.2 Considerations in Designing Formulations for Preclinical Species	456
17.3 Use of API Properties to Guide Formulation Design	460
17.4 Formulations for BCS Class I/III Compounds	463
17.5 Formulations for BCS Class II/IV Compounds Using Enabling Technologies	465
17.6 Evaluating Formulation Performance by In Vitro Dissolution	482
17.7 Rationale Selection of Formulations Suitable for Intended Studies	486
17.8 Case Study	488
Acknowledgments	491
References	491

18. Rational Design for Amorphous Solid Dispersions

A. NEWMAN

18.1 Introduction	497
18.2 Key Components of Amorphous Solid Dispersions	497
18.3 Characterization of Amorphous Dispersions	499
18.4 Screening and Selection of Amorphous Solid Dispersions	501
18.5 Stability Considerations	504
18.6 Solubility and Dissolution Considerations	505
18.7 Methods of Manufacturing Amorphous Solid Dispersions	507
18.8 Dosage Form Development Considerations	509
18.9 Case Studies	509
18.10 Conclusions	515
References	515

19. Rational Design of Oral Modified-Release Drug Delivery Systems

Y. QIU AND P.I. LEE

19.1 Introduction	519
19.2 Oral MR Technologies and Drug Delivery Systems	521
19.3 Rational Design of Modified Release Systems	538
19.4 Summary	550
References	550

20. Product and Process Development of Solid Oral Dosage Forms

Y. QIU, X. HE, L. ZHU AND B. CHEN

20.1 Introduction	555
20.2 Development of Solid Dosage Forms	556
20.3 Technology Transfer	574
20.4 Case Studies	578
20.5 Intellectual Property Considerations	587
20.6 Summary	588
References	589

21. Analytical Development and Validation for Solid Oral Dosage Forms

X.(F) FANG, G. CARR AND R.C. FREEZE

21.1 Analytical Method Development and Validation Strategy	593
21.2 Category of Analytical Method and Method Development	595
21.3 Analytical Method Validation	597
21.4 Method Transfers	606
21.5 Case Studies	607
21.6 Conclusions	610
References	610

22. Statistical Design and Analysis of Long-Term Stability Studies for Drug Products

D. LEBLOND

22.1 Stability Study Objectives	613
22.2 Regulatory Guidance	613
22.3 Test Methods and Data Management	614
22.4 Modeling Instability	615
22.5 Long-Term Stability Study Design	618
22.6 Determination of Shelf Life	625
22.7 Release Limit Estimation	628
22.8 Probability of Future OOS Stability Test Results	629
Appendix A Sample Data	634
References	634

23. Packaging Selection for Solid Oral Dosage Forms

Y. CHEN

23.1 Introduction	637
23.2 Material Considerations	638

23.3 Linking Packaging Property With Drug Property	646	27.2 Gelatin and Capsule Shell Composition	725
23.4 Postapproval Packaging Changes	649	27.3 Capsule Shell Manufacturing	729
References	650	27.4 Alternatives to Gelatin	730
		27.5 Hard Shell	731
		27.6 Capsule Filling	734
		27.7 Capsule Formulation Requirements	740
		27.8 Capsule Formulations	744
		References	746
24. Clinical Supplies Manufacture: Strategy, GMP Considerations, and Cleaning Validation			
B.W. PACK, S. STITHIT AND W. CHEN			
24.1 Introduction	653	28. Design, Development, and Scale-Up of the High-Shear Wet Granulation Process	
24.2 Strategy of Clinical Supplies Manufacture	653	S. BADAWEY AND P. PANDEY	
24.3 Clinical Plan	654	28.1 Introduction	749
24.4 Clinical Supplies Liaison	655	28.2 Rate Processes in Wet Granulation	751
24.5 Lean Manufacturing	655	28.3 Material Properties in Wet Granulation	753
24.6 Cross-Functional Training	657	28.4 Design of the Pharmaceutical Wet Granulation Process	757
24.7 Outsourcing of Manufacturing and Packaging	658	28.5 Quality Attributes of Wet Granulated Products	760
24.8 New Technology	658	28.6 Scale-Up of the High-Shear Wet Granulation Process	764
24.9 GMP Considerations on Manufacturing Clinical Supplies	660	28.7 Modeling and Simulation in High-Shear Wet Granulation	769
24.10 Cleaning Validation and Verification	664	28.8 Summary	772
24.11 Case Study	672	References	772
24.12 Summary	674		
Acknowledgments	674	29. Process Development, Optimization, and Scale-Up: Fluid-Bed Granulation	
References	674	K. YAMAMOTO AND Z.J. SHAO	
		29.1 Overview of the Fluid-Bed Granulation Process	777
25. Specification Setting and Manufacturing Process Control for Solid Oral Drug Products		29.2 Equipment Design	777
W. CHEN, S. STITHIT AND J.Y. ZHENG		29.3 Fluid-Bed Hydrodynamics	781
25.1 Introduction	677	29.4 Mechanisms of Agglomeration	783
25.2 Specifications for the Drug Substance	678	29.5 Formulation and Process Variables and Their Control	784
25.3 Specifications for Clinical Trial Materials	682	29.6 Scale-Up Considerations	786
25.4 Specifications for Commercial Drug Products	684	29.7 Application of Quality-by-Design to Fluid-Bed Granulation	790
25.5 Process Control for Solid Oral Drug Products	687	29.8 Summary	790
25.6 Analytical Procedures	691	References	791
25.7 Conclusions	692		
Acknowledgments	692	30. Formulation, Process Development, and Scale-Up: Spray-Drying Amorphous Solid Dispersions for Insoluble Drugs	
References	692	B. VIG AND M. MORGEN	
		30.1 Introduction	793
26. Process Development, Optimization, and Scale-Up: Providing Reliable Powder Flow and Product Uniformity		30.2 Background	793
T. BAXTER AND J. PRESCOTT		30.3 SDD Formulation Composition	795
26.1 Introduction	695	30.4 SDD Process Considerations: Manufacturing and Scale-Up	803
26.2 Common Powder Handling Equipment	698	30.5 SDD Characterization	809
26.3 Typical Flow and Segregation Concerns	702	30.6 Dosage Form Considerations	815
26.4 Measurement of Flow Properties	707	30.7 Concluding Remarks	817
26.5 Basic Equipment Design Techniques	716	References	818
References	722		
		27. Capsules Dosage Form: Formulation and Manufacturing Considerations	
S.W. HOAG		27.1 Introduction—Capsules as a Dosage Form	723

31. Process Development and Scale-Up: Twin-Screw Extrusion

B. CHEN, L. ZHU, F. ZHANG AND Y. QIU

31.1 Introduction	821
31.2 Twin-Screw Extruder and Extrusion Process	822
31.3 Hot-Melt Extrusion	835
31.4 Continuous Granulation Using a Twin-Screw Extruder	842
31.5 Process Scale-Up	853
31.6 Case Studies	860
31.7 Summary	865
References	865

32. Development, Scale-Up, and Optimization of Process Parameters: Roller Compaction Theory and Practice

J.M. ROWE, S.T. CHARLTON AND R.J. McCANN

32.1 Introduction	869
32.2 In-Process Analytical Characterization Tools	877
32.3 Roller Compaction Models	889
32.4 Approaches to Developing a Roller Compaction Process	903
32.5 Illustrative Example Detailing the Typical Drug Product Development Process for a Roller Compacted Product	906
32.6 Scale-Up Considerations of Roller Compaction	907
32.7 Illustrative Example Detailing a Possible Approach to Scaling-Up a Roller Compaction Process	909
32.8 Trouble-Shooting	912
32.9 Conclusions	912
References	912

33. Development, Optimization, and Scale-Up of Process Parameters: Tablet Compression

D. NATOLI, M. LEVIN, L. TSYGAN AND L. LIU

33.1 Introduction	917
33.2 Operation Principles of Compression by Rotary Press	917
33.3 Tool Design	917
33.4 Tablet Designs	929
33.5 Care of Punches and Dies	936
33.6 Tooling Inspection	936
33.7 Tooling Reworking	937
33.8 Press Wear	937
33.9 Purchasing Tablet Compression Tooling	937
33.10 Consideration of Tooling	938
33.11 Application of Quality by Design and Tools (Case Study)	938
33.12 Scale-Up of Compression	940
References	950

34. Development, Optimization, and Scale-Up of Process Parameters: Pan Coating

S. PORTER, G. SACKETT AND L. LIU

34.1 Introduction	953
34.2 Film-Coating Formulations	954
34.3 Design and Development of Film-Coating Processes	966
34.4 Troubleshooting	986
34.5 Consideration of Product Substrate	987
34.6 Coating Formulation	988
34.7 Application of Systematic and Statistical Tools for Trouble Shooting and Process Optimization	993
References	996

35. Development, Optimization, and Scale-Up of Process Parameters: Wurster Coating

D. JONES AND E. GODEK

35.1 Introduction	997
35.2 Basic Design	997
35.3 HS Wurster Considerations	999
35.4 Coating and Process Characteristics	1000
35.5 Processing Examples	1000
35.6 Process Variables	1002
35.7 Case Studies for Layering and Fine Particle Coating	1005
35.8 Scale-Up of Wurster Processing	1009
35.9 Summary	1014

36. Commercial Manufacturing and Product Quality

D.Y. PENG, Y. HU, S. CHATTERJEE AND D. ZHOU

36.1 Introduction	1015
36.2 Process Design, Understanding, and Control Strategy Development	1016
36.3 Process Scale-Up, Technology Transfer, and Process Qualification	1017
36.4 Continued Process Verification	1020
36.5 Summary	1028
References	1029

37. Emerging Technology for Modernizing Pharmaceutical Production: Continuous Manufacturing

T. O'CONNOR AND S. LEE

37.1 Introduction	1031
37.2 Challenges for Pharmaceutical Manufacturing	1031
37.3 The Adoption of Emerging Technology to Address Pharmaceutical Manufacturing Challenges	1032
37.4 Technologies for Continuous Drug Product Manufacturing	1034
37.5 Challenges in Implementing Continuous Manufacturing	1043
37.6 Conclusion	1044
References	1044

IV

REGULATORY ASPECTS OF PRODUCT DEVELOPMENT

38. Drug Product Approval in the United States and International Harmonization

L. WU, H. SMITH, H. ZHENG AND L.X. YU

38.1 Drug Product Approval and the US Food and Drug Administration	1049
38.2 The New Drug Application Process	1055
38.3 The Abbreviated New Drug Application Process	1064
38.4 The Biologic License Application Process	1069
38.5 Postapproval Activities and Life Cycle Management of NDAs, ANDAs, and BLAs	1071
38.6 Global Perspectives on Product Registration and Drug Approval	1072
Acknowledgments	1074
References	1074

39. Modern Pharmaceutical Regulations: Quality Assessment for Drug Substances

H. ZHANG, D. JOHNSON, D. SKANCHY AND L.X. YU

39.1 Introduction	1079
39.2 Origin of the QbR	1080

39.3 Evolution of the Drug Substance Review Process	1080
39.4 Quality Assessment for Drug Substances	1081
39.5 Conclusion	1090
Appendix QbR Questions—Drug Substance	1091
References	1092

40. Modern Pharmaceutical Regulations: Quality Assessment for Drug Products

J.A. MAGUIRE, W. JIANG AND L.X. YU

40.1 Introduction	1095
40.2 QbR History	1095
40.3 Current Status of QbR	1096
40.4 QbR Questions	1097
40.5 Future Direction	1121
40.6 Conclusions	1122
Appendix: QbR Questions	1122
References	1124

Index	1127
--------------	-------------